Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While ...

Turkey: A decade-long study from a tertiary care hospital highlights the effectiveness and safety of narrow-band ultraviolet ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1,” published in the March 2025 issue of ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...